The rate of breast cancer specific mortality was higher in patients with both high phosphorylated-CXCR4 expression and low plasma CXCL12 levels than either low plasma CXCL12 or high phosphorylated-CXCR4 expression alone. Here, CXCL12 is linked to breast cancer.